Living with Idiopathic Pulmonary Fibrosis (IPF)

Discover ENV-101: Targeting the main driver of fibrosis to revolutionize IPF care.

Idiopathic Pulmonary Fibrosis:
Understanding the Challenge

IPF is a lung disease that causes lung scarring, leading to shortness of breath and persistent cough. Over time, the disease can progress, making it increasingly difficult to breathe, affecting overall quality of life.

Current treatments, pirfenidone (Esbriet®), and nintedenib (Ofev®), may help to slow the progress of IPF in some patients. Your doctor may also recommend treatment with a lung transplant. A deeper understanding and innovative solutions are urgently needed.

Introducing ENV-101:
A New Possibility for IPF Patients

ENV-101 isn't just a molecule; it's a potential game-changer for IPF care. By inhibiting the Hedgehog (Hh) signaling pathway, a known driver of IPF, ENV-101 stands out in its approach.

Innovative Therapy

Specifically for idiopathic pulmonary fibrosis (IPF) – where the Hedgehog pathway is implicated as a driver of the disease.

Clinical Studies

Several dose levels of ENV-101 have already been investigated in studies of healthy participants, patients with advanced cancer, and patients with IPF.

Future Study

The phase 2a trial for ENV-101 is ongoing and we are excited to continue to understand the way our drug works in future trials, including the Phase 2b trial planned for 2024.

ENV-101's 2024 Study:
Diving Deeper into IPF Treatment Possibilities

Coming up in 2024, we'll embark on a comprehensive study to further uncover the capabilities of ENV-101. This new research will specifically evaluate the effect of ENV-101 on lung function among participants with IPF. Moreover, it aims to shed light on the tolerability of ENV-101 and its impact on individual well-being and overall quality of life.

If you are interested in learning more about the enrollment for Endeavor’s upcoming WHISTLE clinical trial, please fill out our form below for email updates.